Mechanism of action: inebiluzmab is a humanized MAB against CD19-positive B-cells which include pre-B cell, immature B-cell, memory B-cell, and plasmablasts. Inebilizumab produces selective depletion of CD19-positive B-cells therefore reducing production of the pathogenic antibody and dampening...
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Orphan Drug Status Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Yes - Neuromyelitis optica; Scleroderma; Myasthenia gravis New Molecular Entity Yes Hi...
How does Uplizna work (mechanism of action)? In people with neuromyelitis optica spectrum disorder (NMOSD) or immunoglobulin G4-related disease (IgG4-RD), the immune system mistakes healthy cells as foreign substances and attacks them. Uplizna is thought to work by destroying certain immune ce...
Uplizna (inebilizumab-cdon) is proven and medically necessary for the treatment of neuromyelitis optica spectrum disorder (NMOSD) when all of the following criteria are met :Initial Therapy Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) by a neurologist, confirming all of the ...
Mechanism Of Action The precise mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD and IgG4-RD is unknown but is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes,...
Action inhibitors Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors),ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) Therapeutic Areas NeoplasmsImmune System DiseasesInfectious Diseases+ [6] Active Indication Immunoglobulin G4-Related DiseaseAQP4-IgG positive Neuromyelitis optica...
In animal models, infusion of AQP4-IgG produces NMO-like lesions through an NK-cell-mediated mechanism [13]. Importantly, tissue injury mediated by autoantibodies often leads to the production of inflammatory cytokines, some of which, such as interleukin-6 (IL-6), further augment autoantibody ...